Navigation Links
Savient Pharmaceuticals to Present at the Citi 2011 Global Healthcare Conference
Date:2/17/2011

EAST BRUNSWICK, N.J., Feb. 17, 2011 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that John H. Johnson, Chief Executive Officer of Savient will present at the Citi 2011 Global Healthcare Conference on Tuesday, March 1, 2011, at 4:00 p.m. Eastern Time.  The conference will be held at the New York Hilton in New York, NY.  

A live webcast of the presentation can be accessed through the investor relations section of the Company's website www.savient.com.  Following the live presentation, a replay of the webcast will be available on the Company's website for 30 days.

ABOUT SAVIENT PHARMACEUTICALS, INC.

Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA™ (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View Pharmaceuticals, Inc. ("MVP").  Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA. MVP and Duke have been granted U.S. and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA.  Savient also manufactures and supplies Oxandrin® (oxandrolone tablets, USP) CIII in the U.S.

SVNT - G


'/>"/>
SOURCE Savient Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related biology technology :

1. Savient Pharmaceuticals to Hold Third Quarter 2008 Financial Results Conference Call on Thursday, November 6, 2008
2. Savients Pegloticase Data in Treatment-Failure Gout Patients Presented at 72nd Annual Meeting of the American College of Rheumatology Conference
3. Savient Submits Biologics License Application (BLA) for pegloticase
4. Savient Pharmaceuticals Reports Third Quarter 2008 Financial Results
5. Savient Pharmaceuticals to Present at the Lazard Capital Markets 5th Annual Healthcare Conference on November 18th
6. Savient Announces Appointment of David Gionco as Chief Financial Officer
7. Savient Pharmaceuticals to Hold Fourth Quarter and Year-End 2008 Results Conference Call on Thursday, February 26, 2009
8. Savient Pharmaceuticals to Raise $31 Million Through Registered Direct Offering
9. Savient Pharmaceuticals Reports First Quarter 2009 Financial Results
10. Savient Announces New Date for FDA Arthritis Advisory Panel Review of KRYSTEXXA(TM) for Treatment Failure Gout
11. Savient Provides Update on Meeting with U.S. Food and Drug Administration for KRYSTEXXA(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... (PRWEB) May 23, 2013 SynCardia Systems, ... and only FDA, Health Canada and CE (Europe) approved ... Centre in Scotland, which boasts more than 380,000 visitors ... Heart powered by the Freedom® portable driver as ... the most advanced exhibitions of its kind. , ...
(Date:5/23/2013)... 2013 Ralph Huber, President of PHI ... management products and emergency survival kits would be on ... made at the quarterly executive board meeting on May 22nd. ... silence for the Oklahoma tornado victims and used the opportunity ... their emergency kits is paramount. “When disaster strikes,” he ...
(Date:5/22/2013)... Cambridge Semantics was one of just ... Day” on Capitol Hill, hosted by The Data ... others to showcase how innovative data management applications can address ... (DATA Act). , Originally introduced in 2011 by Committee ... Mark Warner (D-VA ), the DATA Act is ...
(Date:5/22/2013)... NEW ORLEANS , May 22, 2013 ... of regenerative medicine, presented new data generated in collaboration ... (a leading health economics consultancy) demonstrating the significant healthcare ... and venous leg ulcers (VLU) place upon the US ... research, which reveal annual costs of up to $15 ...
Breaking Biology Technology:SynCardia Total Artificial Heart Featured in $3 Million Exhibition at Glasgow Science Centre 2SynCardia Total Artificial Heart Featured in $3 Million Exhibition at Glasgow Science Centre 3PHI Emergency Management on Announces Father's Day Specials All Emergency Survival Kits 2Cambridge Semantics Underscores Need for Smart Data during “Data Demonstration Day” on Capitol Hill 2Organogenesis Presents Findings from Groundbreaking Research Highlighting the Healthcare Resource and Economic Burden of Venous Leg Ulcers and Diabetic Foot Ulcers 2Organogenesis Presents Findings from Groundbreaking Research Highlighting the Healthcare Resource and Economic Burden of Venous Leg Ulcers and Diabetic Foot Ulcers 3Organogenesis Presents Findings from Groundbreaking Research Highlighting the Healthcare Resource and Economic Burden of Venous Leg Ulcers and Diabetic Foot Ulcers 4
... continue at an accelerated pace, but the challenge now ... for workers here in the United States. We ... equation. We need to identify what investments should be ... environment that fosters new jobs for U.S. tech workers. ...
... company looks to reclaim lost ground , ,CHIPPEWA FALLS, Wis. ... out of offices on Lowater Road here in its hometown, just ... heights. , ,With its next-generation X1, on the market since December ... the future with a twinkle in its corporate eye that, just ...
... Journal? During the course of any week, in my role ... as VP of CCC, I meet many interesting entrepreneurs, IT ... luncheons and events from which I desire to share my ... we can have some fun revisiting my experiences. My first ...
Cached Biology Technology:Are U.S. Tech Jobs in Jeopardy? 2Are U.S. Tech Jobs in Jeopardy? 3Cray Rides Again 2Cray Rides Again 3Mr. Jackson Goes to Washington 2Mr. Jackson Goes to Washington 3Mr. Jackson Goes to Washington 4
(Date:5/21/2013)... analysis shows that the nation,s land and water resources ... produce up to 25 billion gallons of algae-based fuel ... country,s yearly needs. , The findings come from an ... needed to grow significant amounts of algae in large, ... the May 7 issue of Environmental Science and ...
(Date:5/21/2013)... that a class of pharmaceuticals can both prevent and ... known as "TSPO ligands," are currently used for certain ... of TSPO ligand in young adult mice when pathology ... when pathology was quite severe," said lead researcher Christian ... ligand reduced measures of pathology and improved behavior at ...
(Date:5/21/2013)... most deadly when they metastasize and spread tumors throughout ... becomes very difficult for doctors to locate and treat ... the University of Missouri have found a way to ... they may be in the body. Michael Lewis, an ... Veterinary Medicine, says being able to target secondary tumors ...
Breaking Biology News(10 mins):Going green: Nation equipped to grow serious amounts of pond scum for fuel 2Going green: Nation equipped to grow serious amounts of pond scum for fuel 3Going green: Nation equipped to grow serious amounts of pond scum for fuel 4Drugs found to both prevent and treat Alzheimer's disease in mice 2MU researchers develop radioactive nanoparticles that target cancer cells 2
... number of cases, scientists at Johns Hopkins have discovered the ... dystrophy, FCD, the leading reason for corneal transplantation in the ... deterioration of the cells covering the clear, outermost lens of ... over 40. Late in life, the dystrophy causes swelling of ...
... into a possible new cancer drug suggests that it ... than current chemotherapeutic drugs. , Dr David Huang, Dr ... WEHI's cancer research divisions have been assessing the potential ... US-based healthcare company, Abbott. , Under normal ...
... spite of our long and painful relationship with Campylobacter ... about the bug that is the leading cause of ... of the most common causes of diarrhea worldwide. The ... million Americans a year. , While most sufferers ...
Cached Biology News:Leading reason for corneal transplants comes into focus 2Leading reason for corneal transplants comes into focus 3Hope for a more effective and less toxic cancer drug 2The biggest bug in gut discomfort 2
... Ac-DEVD-CHO is an inhibitor ... The concentration of inhibitor ... activity must be determined ... Ten micromolar inhibitor is ...
Human RELT/TNFRSF19L Affinity Purified Polyclonal Ab...
Mouse NOV/CCN3 Affinity Purified Polyclonal Ab...
HiTrap NHS-activated HP, 1 x 5 ml. Category: Chromatography Systems & Accessories, Systems....
Biology Products: